JNJ- Johnson & Johnson
Johnson & Johnson (JNJ) has 23 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. JNJ is classified in the Pharmaceuticals industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 4.04M | $1.05B | - | |
| VP | 114.3K | $29.60M | - | |
| CEO | 79.6K | $20.62M | - | |
| VP | 46.2K | $11.97M | - | |
| VP | 46.1K | $11.93M | -23,054 |
Activity
Buys and sells only
Transactions
10 filings · page 3
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 8,891 | $162.16 | $1,441,764.56 | -37.1% | -8.9% | +1.2% | |
| Feb 16, 2024 | Johnson & Johnson59 | 10% Owner | Sale+OE | 3,725 | $25.81 | $96,142.25 | - | -1.5% | -0.3% | |
| Feb 9, 2024 | Taubert Jennifer L60 | EVP, Ww Chair, Pharmaceuticals | Sale+OE | 59,397 | $156.27 | $9,281,969.19 | -29.6% | -4.4% | -2.3% | |
| Jul 26, 2023 | Hait William65 | See Remarks | Sale+OE | 14,698 | $172.00 | $2,528,056.00 | -14.3% | -12.4% | -7.6% | |
| Jul 25, 2023 | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 20,000 | $170.32 | $3,406,498.00 | -16.3% | -12.2% | -9.3% | |
| Jun 12, 2023 | Wengel Kathryn E61 | EVP, Chief To And Risk Officer | Sell | 12,465 | $160.00 | $1,994,400.00 | -15.9% | +1.7% | -8.2% | |
| Mar 6, 2023 | Swanson James D. | See Remarks | Sell | 1,062 | $154.66 | $164,199.44 | -10.3% | +1.8% | +2.8% | |
| Dec 13, 2022 | Wolk Joseph J | Exec VP, CFO | Sale+OE | 14,781 | $179.60 | $2,654,660.91 | -14.9% | -14.6% | -13.1% | |
| Nov 30, 2022 | McEvoy Ashley | EVP, Ww Chair, Medtech | Sale+OE | 73,323 | $175.47 | $12,865,800.76 | -32.0% | -13.9% | -13.1% | |
| Nov 22, 2022 | Taubert Jennifer L60 | EVP, Ww Chair, Pharmaceuticals | Sale+OE | 76,923 | $176.78 | $13,598,401.79 | -37.8% | -10.6% | -14.7% |